Main Article Content
Prevalence of extended spectrum β-lactamases (ESBLs) among clinical Enterobacteriaceae isolates obtained from private diagnostic laboratory in Kano - Nigeria
Abstract
One hundred Gram negative bacterial isolates were collected from a private diagnostic center and identified by subjecting the isolates to biochemical tests using standard procedures. Confirmed Enterobacteriaceae isolates were further subjected to screening for extended spectrum â-lactamases (ESBLs) production using Clinical Laboratory Standards Institute (CLSI) breakpoint and Double Disc Synergy Test (DDST). Standard discs of Augmentin (AUG 30 ìg) {Optudisc} and Ceftriaxone (CXM 30 ìg) {Medireich} and Ceftazidime (CAZ 30 ìg) {Glaxo-Smithkline} were used in the screening. The results of CLSI breakpoint test showed that 87% were ESBLs producers viz: Citrobacter fruendii (3), Escherichia coli (46), Klebsiella pneumoniae (13), Morganella morganii (1), Proteus vulgaris (23) and Salmonella typhi (1) while that of
confirmed ESBLs producers using DDST was 49%. These included Citrobacter fruendii (2), Escherichia coli (25), Klebsiella pneumoniae (7), Morganella morganii (1), Proteus vulgaris (13) and Salmonella typhi (1). The implication of the results is discussed.
confirmed ESBLs producers using DDST was 49%. These included Citrobacter fruendii (2), Escherichia coli (25), Klebsiella pneumoniae (7), Morganella morganii (1), Proteus vulgaris (13) and Salmonella typhi (1). The implication of the results is discussed.